de-DEen-US
Zum Inhalt springen
Ressourcen zur psychedelischen Forschung und Bewusstseinserweiterung (LSD Derivate)

Wissenschaftliche Forschung

Bedeutung und Potenzial von Psychedelika in der Wissenschaft

Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression
Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression

Zusammenfassung

Phase 2b dose-ranging trial (COMP360) in 233 participants with treatment-resistant depression. The 25 mg psilocybin group showed significantly greater reduction in MADRS depression score at week 3 compared to the 1 mg control group.

Schlüsselwörter

psilocybintreatment-resistant depressionCOMP360phase 2bCOMPASS Pathways
Klinische Forschung